A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status:
Completed
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This is an open label, single arm phase 1 dose escalation study and phase 2 study of BBI608
in combination with paclitaxel in patients with advanced malignancies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Boston Biomedical, Inc Sumitomo Dainippon Pharma Oncology, Inc